Shahzad Raza, MD, on Relapsed/Refractory Multiple Myeloma: Novel Doublet in Patients With Extramedullary Disease

December 08, 2025 By The ASCO Post Staff

Shahzad Raza, MD, of Cleveland Clinic, presents updated phase II results of the RedirecTT-1 trial, focusing on the efficacy and safety of talquetamab combined with teclistamab in patients with relapsed/refractory multiple myeloma and extramedullary disease (Abstract 698). The study also received simultaneous publication in The New England Journal of Medicine.

Related Content